COMPASS Pathways plc (NASDAQ:CMPS) Shares Acquired by Brown University

Brown University grew its stake in COMPASS Pathways plc (NASDAQ:CMPS) by 194.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 214,200 shares of the company’s stock after purchasing an additional 141,500 shares during the period. COMPASS Pathways makes up approximately 0.3% of Brown University’s portfolio, making the stock its 12th biggest holding. Brown University owned about 0.31% of COMPASS Pathways worth $810,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Propel Bio Management LLC purchased a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $504,000. Acuta Capital Partners LLC purchased a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $2,435,000. Walleye Capital LLC purchased a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $2,126,000. Sio Capital Management LLC boosted its stake in shares of COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after buying an additional 621,222 shares in the last quarter. Finally, Polar Asset Management Partners Inc. boosted its stake in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after buying an additional 258,000 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CMPS. Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Stock Down 0.3 %

Shares of NASDAQ:CMPS opened at $3.48 on Monday. The company has a market capitalization of $322.50 million, a P/E ratio of -1.58 and a beta of 2.29. The stock’s fifty day simple moving average is $4.00 and its 200-day simple moving average is $4.98. COMPASS Pathways plc has a 52-week low of $3.17 and a 52-week high of $10.31. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities research analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.